Advertisement

Potassium Acetate Injection

[08 May 2014]

Products Affected - Description

Potassium acetate injection, 2 meq/mL, American Regent
20 mL vial (NDC 00517-2053-25)

Potassium acetate injection, 4 meq/mL, American Regent
50 mL vial (NDC 00517-5024-25)

Reason for the Shortage

  • Hospira states the shortage was due to manufacturing delays.
  • Hospira and American Regent discontinued potassium acetate 2 meq/mL 100 mL bulk packages.
  • American Regent had temporarily suspended manufacture of most drug products including potassium acetate in April, 2011.
  • American Regent resumed manufacturing in Shirley, New York in early-May, 2011.

Available Products

Potassium acetate injection, 2 meq/mL, Hospira
20 mL vial (NDC 00409-8183-01)
50 mL vial (NDC 00409-3294-51)

Estimated Resupply Dates

American Regent has potassium acetate 2 meq/mL 20 mL vials and 4 meq/mL 50 mL vials on back order and the company cannot estimate a release date.  

Related Shortages

Updated

May 8, 2014; February 26, 2014; January 3, 2014; December 27, 2013; November 6, 2013; September 19, 2013; August 9, 2013; June 27, 2013; June 6, 2013; May 30, 2013; April 29, 2013; April 1, 2013; March 25, 2013; March 7, 2013; December 14, 2012, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement